Austin Ma, MD
Hematology & Oncology · Los Angeles, CANPI 1598700627
Payments from drug & device makers
Across 197 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$723
- Beigene USA, Inc.$619
- Pfizer$380
- Astellas Pharma US Inc$248
- Array Biopharma Inc$235
- AstraZeneca$223
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,33491%
- Education$4079%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 39 | $723 |
| Beigene USA, Inc. | 22 | $619 |
| Pfizer | 18 | $380 |
| Astellas Pharma US Inc | 5 | $248 |
| Array Biopharma Inc | 11 | $235 |
| AstraZeneca | 7 | $223 |
| Beone Medicines USA, Inc. | 8 | $221 |
| AbbVie | 9 | $196 |
| GSK | 7 | $192 |
| Lilly USA, LLC | 10 | $182 |
| Sobi, Inc | 3 | $161 |
| Seagen Inc. | 2 | $122 |
| Gilead | 4 | $100 |
| Puma Biotechnology, Inc. | 5 | $99 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| EMD Serono, Inc. | 4 | $77 |
| US Oncology Corporate, Inc. | 2 | $75 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Bristol Myers Squibb | 2 | $52 |
| Incyte Corporation | 2 | $50 |
| Eisai Inc. | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Verastem, Inc. | 2 | $45 |
| Bayer | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Merck | 1 | $32 |
| Johnson & Johnson | 2 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $28 |
| Foundation Medicine, Inc. | 1 | $27 |
| Aurobindo Pharma USA, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $16 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$126
How this compares
$4,741 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 84 | $1,517,976 |
| XtandiEnzalutamide | 64 | $896,091 |
| Lenalidomide | 43 | $594,909 |
| IbrancePalbociclib | 20 | $326,650 |
| ProcritEpoetin Alfa | 95 | $293,954 |
| BrukinsaZanubrutinib | 19 | $278,337 |
| Lupron DepotLeuprolide Acetate | 47 | $269,797 |
| JakafiRuxolitinib Phosphate | 11 | $257,836 |
| TagrissoOsimertinib Mesylate | 14 | $215,926 |
| ZejulaNiraparib Tosylate | 11 | $116,639 |
| Abiraterone Acetate | 70 | $100,084 |
| ZarxioFilgrastim-Sndz | 48 | $33,668 |
| EligardLeuprolide Acetate | 24 | $30,085 |
| Imatinib Mesylate | 19 | $25,784 |
| EliquisApixaban | 19 | $17,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $83 | $1,517,97684 claims |
| Astellas Pharma US IncXtandi | $248 | $896,09164 claims |
| PfizerIbrance, Eliquis | $380 | $343,84039 claims |
| Johnson & JohnsonProcrit | $31 | $293,95495 claims |
| Beigene USA, Inc.Brukinsa | $619 | $278,33719 claims |
| AbbVieLupron Depot | $196 | $269,79747 claims |
| Incyte CorporationJakafi | $50 | $257,83611 claims |
| AstraZenecaTagrisso | $223 | $215,92614 claims |
| GSKZejula | $192 | $116,63911 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $20 | $30,08524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.